GVR Report cover Nebulizer Market Size, Share & Trends Report

Nebulizer Market Size, Share & Trends Analysis Report By Type (Jet, Mesh, Ultrasonic), By End Use (Hospitals & Clinics, Emergency Centers, Home Healthcare), And Segment Forecasts, 2022 - 2030

  • Report ID: GVR-2-68038-069-9
  • Number of Pages: 100
  • Format: Electronic (PDF)
  • Historical Range: 2017 - 2020
  • Industry: Healthcare

Report Overview

The global nebulizer market size was valued at USD 1.04 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.2% from 2022 to 2030. The high growth is attributed to the rising incidence rate of chronic respiratory diseases, increasing demand for home healthcare devices, and the rising geriatric population. As per the Centers for Disease Control and Prevention, Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in the U.S.

North America nebulizer market size, by type, 2020 - 2030 (USD Million)

Moreover, the rising consumption of alcohol, tobacco, and ultra-processed products, including sugar-sweetened beverages, is a major cause behind the increasing prevalence of respiratory diseases in North America. According to the Centers for Disease Control and Prevention (CDC) data, about 14% of deaths in adults aged 30 to 70 years in North America are caused due to tobacco consumption. Thus, an increase in the number of smokers and environmental pollution are anticipated to increase the demand for nebulizers. In addition, as per the WHO, in 2019, there were around 3.23 million deaths worldwide due to COPD. However, initiatives such as the “Global Alliance against Chronic Respiratory Diseases” are likely to improve diagnosis and treatment rates of respiratory disorders, which may, in turn, drive the market for nebulizers.

The COVID-19 outbreak has affected millions of people around the world. The pandemic has compelled the healthcare industry to take emergency actions, with a race to develop both therapeutic and preventive interventions. Asthma or COPD patients, who were aware of the risk of airborne transmission of COVID-19, were hesitant with regard to the use of inhaled medications, which are considered a potential source of viral transmission and immunosuppression. However, medical practitioners advised all such patients to continue using their prescribed inhaled medications, including nebulizers. Nebulized albuterol was recommended in some parts of the U.S. as an alternative to albuterol rescue inhalers when pharmacies faced a shortage of albuterol inhalers.

In addition, many pharmaceutical corporations are focusing on developing effective treatments to treat the COVID-19 viruses, which will be primarily administered via a nebulizer. For instance, in May 2021, Inspira Pharmaceuticals and Vectura declared a collaboration to develop a potential inhalation-based COVID-19 therapy. Under this contract, Vectura will test IPX formulation delivery to lungs through its FOX vibrating mesh nebulizer.

The market for nebulizers and respiratory devices is quite mature with the jet segment dominating the market due to the low cost. Hence, other nebulization devices are expected to experience high competition. Furthermore, it is a challenge for new technology or device to gain momentum in mature markets, particularly with the intricacies of different reimbursement and national regulatory systems that need to be followed for both drugs as well as devices.

Furthermore, it is a challenge for new technology or device to gain momentum in mature markets, particularly with the intricacies of different reimbursement and national regulatory systems that need to be followed for both drugs as well as devices. Mesh nebulizers are more expensive than jet nebulizers because of the increased number of tolerances, components, critical parts, and assembly related to both mesh and electronic control circuits. Besides, increasing applications of mesh nebulizers in clinical trials since 2006 by major companies such as Philips, Vectura, and Pari Gmbh are expected to boost the market growth in the near future.

Medicare Part B covers the cost of nebulizers and the cost of a few nebulizer medicines that are considered necessary. Under Part C, coverage is provided for medically-necessary nebulizers. Medicare reimburses 75% of the manufacturer’s suggested retail price for durable medical equipment. Nebulizers are classified as durable medical equipment by Medicare. Initiatives are being undertaken by government and non-government organizations to streamline the diagnosis and treatment of respiratory disorders, thus further supporting the market growth. For instance, the GARD is a voluntary alliance of national and international organizations to cure respiratory disorders.

Type Insights

Jet nebulizers accounted for the largest revenue share of over 65.0% in 2021 owing to the low cost of the devices. Besides, ease of handling nebulizers and efficient design for drug delivery have made jet nebulizers the prime segment over the years. Jet nebulizers are effective in delivering formulations that cannot be delivered with dry powder inhalers and pressurized metered-dose inhalers. In addition, nebulizers are available in various designs including jet nebulizers along with corrugated tubes, collection bags, breath-enhanced and breath-actuated jet nebulizers, and others.

The mesh nebulizers segment is expected to witness lucrative growth over the forecast period due to the technologically advanced compact size devices and minimized drug loss. The market for mesh nebulizers is expected to grow further, majorly due to increased patient acceptance, quick treatment, portability, and convenience. Furthermore, increasing commercial acceptance of mesh nebulizers due to accurate drug delivery to the lung and lower residual volumes also aids in market penetration. Some of the products offered by the key players in the market are Omron Corporation’s MicroAIR U100 (compact, travel-ready, with mesh technology) and Philips Healthcare’s Aeroneb Go (Portable nebulizer based on Aerogen’s vibration mesh technology for patients requiring respiratory aerosol therapy).

End-use Insights

The hospitals and clinics segment accounted for the largest revenue share of over 65.0% in 2021 owing to the favorable reimbursement policies and larger patient footfall. Hospitals are an integral part of the healthcare industry and are the major revenue source for the entire industry. Therefore, multiple companies invest substantial efforts, both in terms of marketing strategies and revenue, to endorse their product/services in the hospitals. Besides, in December 2021, Cipla Limited revealed an initiative to enhance access to nebulization therapy for acute asthma management in primary healthcare centers of rural India. Thus, such projects boost the segment growth.

"Global

Home healthcare devices have been gaining popularity and market share in recent years. Miniaturization of products and technological advancements are boosting the adoption of home healthcare devices. Furthermore, the growing geriatric population, high incidence of target diseases, and growing need to curb healthcare expenditure are expected to be some of the high-impact rendering drivers for home healthcare devices. Home healthcare is a cost-effective alternative to expensive hospital stays, which is expected to boost the market growth. Easy availability of compact nebulizers that are ideal for home use and technological innovations in nebulizers to reduce the sound created by them and improve their functionality are increasing their adoption in home healthcare.

Regional Insights

North America captured the largest revenue share of over 30.0% in 2021 owing to growing respiratory disorders and efforts by the government such as favorable reimbursement scenario, rise in customer awareness, and well-established healthcare infrastructure. Furthermore, the introduction of technologically advanced devices and favorable reimbursement scenarios in this region is expected to fuel market growth in this region. Moreover, a rise in the geriatric population in the U.S. is leading to a corresponding growth in the number of surgeries in the country, which further boosts the regional market growth. For instance, the number of Americans aged 65 and older will more than double over the next 40 years, reaching 80 million in 2040.

Asia Pacific is expected to be the fastest-growing regional market over the forecast period owing to a large geriatric population, increasing focus on preventive care, and government initiatives promoting technological innovations. A rise in the healthcare expenditure and an increase in patient awareness in the region have created the demand for these devices. Low-cost manufacturing sites and favorable taxation policies in the region’s countries have been successful in attracting foreign players to this market. In addition, the rise in medical tourism in countries such as India, the Philippines, Malaysia, and Singapore has aided the regional market growth.

Key Companies & Market Share Insights

The market for nebulizers is mature due to the presence of major players. However, the introduction of technologically advanced mesh nebulizers has created many opportunities for the companies such as Vectura Group and PARI Pharma. Many pharmaceutical companies are also using mesh nebulizers for drug development. For instance, as per the analysis of the U.S. and Europe clinical trial databases, mesh nebulizers are more preferred for clinical trials sponsored by pharmaceutical companies over jet nebulizers.

To differentiate their products from the other market players, companies are adopting strategies such as new product development, acquisitions, and collaborations with other players or research institutes. For instance, in October 2020, HCmed Innovations Co., Ltd. introduced Pulmogine to the China market. Likewise, in January 2020, OMRON Corporation announced the opening of the Automation Center Tokyo (ATC-TOKYO) in Tokyo. With this center, customers can join the company to find solutions for any challenges arising during manufacturing. Some prominent players in the global nebulizer market include:

  • Omron Corporation

  • GE Healthcare

  • Koninklijke Philips N.V.

  • Allied Healthcare

  • Vectura Group Plc.

  • PARI Respiratory Equipment, Inc.

  • Aerogen

  • DeVilbiss Healthcare LLC

  • Briggs Healthcare

  • Beurer GmBH

Nebulizer Market Report Scope

Report Attribute

Details

Market size value in 2022

USD 1.09 billion

Revenue forecast in 2030

USD 1.77 billion

Growth Rate

CAGR of 6.2% from 2022 to 2030

Base year for estimation

2021

Historical data

2017 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million/billion and CAGR from 2022 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Type, end use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; Germany; U.K.; France; Italy; Spain; China; Japan; India; Singapore; Philippines; Indonesia; Malaysia; Brazil; Mexico; South Africa; Saudi Arabia

Key companies profiled

Omron Corporation; GE Healthcare; Koninklijke Philips N.V.; Allied Healthcare; Vectura Group Plc.; PARI Respiratory Equipment, Inc.; Aerogen; DeVilbiss Healthcare LLC; Briggs Healthcare; Beurer GmBH

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Segments Covered in the Report
 

This report forecasts revenue growth at the global, regional, and country levels, and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2017 to 2030. For this study, Grand View Research has segmented the global nebulizer market report based on type, end use, and region

  • Type Outlook (Revenue, USD Million, 2017 - 2030)
    • Jet

    • Mesh

      • Active

      • Passive

    • Ultrasonic
  • End-use Outlook (Revenue, USD Million, 2017 - 2030)
    • Hospitals & Clinics

    • Emergency Centers

    • Home Healthcare

  • Regional Outlook (Revenue, USD Million, 2017 - 2030)
    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • France

      • Italy

      • Spain

    • Asia Pacific

      • Japan

      • China

      • India

      • Malaysia

      • Philippines

      • Indonesia

      • Singapore

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

Frequently Asked Questions About This Report

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.